Arvinas (ARVN) and Pfizer (PFE) said Tuesday that a phase 3 clinical trial of vepdegestrant monotherapy as an investigational treatment for advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but did not reach statistical significance in progression-free survival improvement in the intent-to-treat population.
The study is evaluating vepdegestrant versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
The companies said vepdegestrant showed a statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in patients whose tumors harbor ESR1 mutations, with the results exceeding the pre-specified target hazard ratio of 0.60.
The trial continues to assess overall survival as a secondary endpoint, the companies said.
Shares of Arvinas were down 43% in recent premarket activity while Pfizer stock was marginally lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.